193 related articles for article (PubMed ID: 32233011)
1. Integrating the immune microenvironment of prostate cancer induced bone disease.
Ihle CL; Owens P
Mol Carcinog; 2020 Jul; 59(7):822-829. PubMed ID: 32233011
[TBL] [Abstract][Full Text] [Related]
2. Distinct tumor microenvironments of lytic and blastic bone metastases in prostate cancer patients.
Ihle CL; Provera MD; Straign DM; Smith EE; Edgerton SM; Van Bokhoven A; Lucia MS; Owens P
J Immunother Cancer; 2019 Nov; 7(1):293. PubMed ID: 31703602
[TBL] [Abstract][Full Text] [Related]
3. Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment.
Kfoury Y; Baryawno N; Severe N; Mei S; Gustafsson K; Hirz T; Brouse T; Scadden EW; Igolkina AA; Kokkaliaris K; Choi BD; Barkas N; Randolph MA; Shin JH; Saylor PJ; Scadden DT; Sykes DB; Kharchenko PV;
Cancer Cell; 2021 Nov; 39(11):1464-1478.e8. PubMed ID: 34719426
[TBL] [Abstract][Full Text] [Related]
4. BHLHE22 drives the immunosuppressive bone tumor microenvironment and associated bone metastasis in prostate cancer.
Yin C; Wang M; Wang Y; Lin Q; Lin K; Du H; Lang C; Dai Y; Peng X
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36941015
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. Targeting the BMP Pathway in Prostate Cancer Induced Bone Disease.
Straign DM; Ihle CL; Provera MD; Owens P
Front Endocrinol (Lausanne); 2021; 12():769316. PubMed ID: 34956082
[TBL] [Abstract][Full Text] [Related]
7. High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot.
Keam SP; Halse H; Nguyen T; Wang M; Van Kooten Losio N; Mitchell C; Caramia F; Byrne DJ; Haupt S; Ryland G; Darcy PK; Sandhu S; Blombery P; Haupt Y; Williams SG; Neeson PJ
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581061
[TBL] [Abstract][Full Text] [Related]
8. Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer.
Kang J; La Manna F; Bonollo F; Sampson N; Alberts IL; Mingels C; Afshar-Oromieh A; Thalmann GN; Karkampouna S
Cancer Lett; 2022 Apr; 530():156-169. PubMed ID: 35051532
[TBL] [Abstract][Full Text] [Related]
9. CD169(+) macrophages mediate pathological formation of woven bone in skeletal lesions of prostate cancer.
Wu AC; He Y; Broomfield A; Paatan NJ; Harrington BS; Tseng HW; Beaven EA; Kiernan DM; Swindle P; Clubb AB; Levesque JP; Winkler IG; Ling MT; Srinivasan B; Hooper JD; Pettit AR
J Pathol; 2016 Jun; 239(2):218-30. PubMed ID: 27174786
[TBL] [Abstract][Full Text] [Related]
10. A humanized orthotopic tumor microenvironment alters the bone metastatic tropism of prostate cancer cells.
McGovern JA; Bock N; Shafiee A; Martine LC; Wagner F; Baldwin JG; Landgraf M; Lahr CA; Meinert C; Williams ED; Pollock PM; Denham J; Russell PJ; Risbridger GP; Clements JA; Loessner D; Holzapfel BM; Hutmacher DW
Commun Biol; 2021 Aug; 4(1):1014. PubMed ID: 34462519
[TBL] [Abstract][Full Text] [Related]
11. Bone metastasis in prostate cancer: Recurring mitochondrial DNA mutation reveals selective pressure exerted by the bone microenvironment.
Arnold RS; Fedewa SA; Goodman M; Osunkoya AO; Kissick HT; Morrissey C; True LD; Petros JA
Bone; 2015 Sep; 78():81-6. PubMed ID: 25952970
[TBL] [Abstract][Full Text] [Related]
12. Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases.
Tabariès S; Ouellet V; Hsu BE; Annis MG; Rose AA; Meunier L; Carmona E; Tam CE; Mes-Masson AM; Siegel PM
Breast Cancer Res; 2015 Mar; 17(1):45. PubMed ID: 25882816
[TBL] [Abstract][Full Text] [Related]
13. How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer.
Stultz J; Fong L
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):697-717. PubMed ID: 33820953
[TBL] [Abstract][Full Text] [Related]
14. Size Matters: Metastatic Cluster Size and Stromal Recruitment in the Establishment of Successful Prostate Cancer to Bone Metastases.
Araujo A; Cook LM; Lynch CC; Basanta D
Bull Math Biol; 2018 May; 80(5):1046-1058. PubMed ID: 29600344
[TBL] [Abstract][Full Text] [Related]
15. Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment.
Vardaki I; Corn P; Gentile E; Song JH; Madan N; Hoang A; Parikh N; Guerra L; Lee YC; Lin SC; Yu G; Santos E; Melancon MP; Troncoso P; Navone N; Gallick GE; Efstathiou E; Subudhi SK; Lin SH; Logothetis CJ; Panaretakis T
Clin Cancer Res; 2021 Jun; 27(11):3253-3264. PubMed ID: 33753455
[TBL] [Abstract][Full Text] [Related]
16. Tumor-infiltrating mesenchymal stem cells: Drivers of the immunosuppressive tumor microenvironment in prostate cancer?
Krueger TE; Thorek DLJ; Meeker AK; Isaacs JT; Brennen WN
Prostate; 2019 Feb; 79(3):320-330. PubMed ID: 30488530
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer multifocality, the index lesion, and the microenvironment.
Tourinho-Barbosa RR; de la Rosette J; Sanchez-Salas R
Curr Opin Urol; 2018 Nov; 28(6):499-505. PubMed ID: 30138121
[TBL] [Abstract][Full Text] [Related]
18. Neutrophils are mediators of metastatic prostate cancer progression in bone.
Costanzo-Garvey DL; Keeley T; Case AJ; Watson GF; Alsamraae M; Yu Y; Su K; Heim CE; Kielian T; Morrissey C; Frieling JS; Cook LM
Cancer Immunol Immunother; 2020 Jun; 69(6):1113-1130. PubMed ID: 32114681
[TBL] [Abstract][Full Text] [Related]
19. Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options.
Gartrell BA; Coleman R; Efstathiou E; Fizazi K; Logothetis CJ; Smith MR; Sonpavde G; Sartor O; Saad F
Eur Urol; 2015 Nov; 68(5):850-8. PubMed ID: 26153564
[TBL] [Abstract][Full Text] [Related]
20. Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis.
Park SH; Keller ET; Shiozawa Y
Calcif Tissue Int; 2018 Feb; 102(2):152-162. PubMed ID: 29094177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
